Cambridge Archives - 2021 CMSC Annual Meeting

October 25, 2021

Characterizing Activities of Daily Living in MS Patients with Processing Speed Scores Above and below a Threshold Previously Shown to Predict Employment Status

Background: Cognitive impairment can occur early in the course of multiple sclerosis (MS) and worsen progressively over time, impacting...

Read More →

Poster-Non-imaging Biomarkers

October 25, 2021

Combinatorial Analysis of Plasma and DNA Methylation Biomarkers in African American Patients with Multiple Sclerosis

Background: African American patients are at increased risk of developing severe forms of multiple sclerosis and have been underrepresented...

Read More →

Poster-Methods of Care

October 25, 2021

Impact of the COVID-19 Pandemic on People with Multiple Sclerosis: Results from an International Survey

Background: The broad impact of the COVID-19 pandemic on people with multiple sclerosis (PwMS) and their health, behaviors, and ability to...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis

Background: Limited data on baseline (BL) characteristics and disease severity exist for Black/African American (AA) patients with multiple...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data

Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Incidence and Severity of Natalizumab Infusion-Related Reactions during Infusion and Postinfusion Observation

Background: Natalizumab, an efficacious treatment for relapsing forms of multiple sclerosis, has an approved dosing of 300 mg infused...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a

Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans

Background: In patients with multiple sclerosis (MS), adherence and persistence to disease-modifying therapies (DMTs) are important to...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 ExperienceUS Study

Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths

Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...

Read More →

2021 CMSC Annual Meeting

Tag: Cambridge

Characterizing Activities of Daily Living in MS Patients with Processing Speed Scores Above and below a Threshold Previously Shown to Predict Employment Status

Combinatorial Analysis of Plasma and DNA Methylation Biomarkers in African American Patients with Multiple Sclerosis

Impact of the COVID-19 Pandemic on People with Multiple Sclerosis: Results from an International Survey

Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis

Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data

Incidence and Severity of Natalizumab Infusion-Related Reactions during Infusion and Postinfusion Observation

Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a

Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans

Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 ExperienceUS Study

COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths

MAILING ADDRESS

CONTACT US

FOLLOW US